Shares of AbCellera Biologics surged 10.1% to $6.52 as investors looked past a bruising quarterly earnings miss and zeroed in on two headline-grabbing partnership deals and a make-or-break drug trial readout now days away.
Big Pharma Is Paying Up for AbCellera's Technology — but the Checks Are Getting Smaller
AbCellera's platform for building T-cell engagers — antibodies designed to direct the immune system against disease targets — reeled in a second client this summer. Vertex Pharmaceuticals paid $28 million upfront, one month after Jazz Pharmaceuticals signed its own deal worth $56 million upfront.
Including a third program trigger, the Jazz deal alone could reach $84 million in upfront payments. Combined, the deals add over $112 million in near-term cash. But for a company burning roughly $55 million per quarter, that buys about two quarters of runway — a helpful but hardly transformative sum.
Revenue Collapsed 76% While Losses Ballooned
Total revenue was $4.1 million, compared to $17.1 million in Q2 2025.
Net loss widened to roughly $55 million, up from $35 million a year earlier,
driven by R&D expenses climbing to $46 million from $39.2 million. The company is spending more to build its own drug pipeline while the older fee-for-service discovery business shrinks — partner-led programs fell from 44 at year-end to 35. That shift is deliberate but painful on the income statement.
A Cushion Exists — for Now
AbCellera ended the quarter with over $565 million in cash and marketable securities, bringing total available liquidity to over $675 million.
Management says this provides a runway of at least three years. That buffer matters because the company has no marketed products generating steady income.
Monday's Data Drop Could Rewrite the Entire Thesis
AbCellera will release top-line Phase 2 data for its lead hot-flash drug on Monday, August 10, 2026, before the market opens.
The company estimates roughly 6 million U.S. women actively seek treatment for moderate-to-severe menopause symptoms,
implying a potential $6 billion market for non-hormonal therapies.
This is the only antibody targeting this mechanism in clinical testing, meaning positive results could validate an entirely new class of treatment. A miss, however, would gut the bull case for a stock that has already risen 132% over the past year largely on pipeline hopes.
The partnership cash is real, the science is promising, and the balance sheet is sturdy. But at ~$2 billion in market value, investors are pricing in success that a single data readout on Monday will either confirm — or shatter.